Benzinga | Oct 13, 2020 06:36AM EDT

Stifel Initiates Coverage On Athira Pharma with Buy Rating, Announces Price Target of $36

Stifel analyst Paul Matteis initiates coverage on Athira Pharma (NASDAQ:ATHA) with a Buy rating and announces Price Target of $36.